October 10, 2016 / 7:11 AM / 9 months ago

BRIEF-Karolinska Development: Aprea Therapeutics updates clinical data of APR-246

1 Min Read

Oct 10 (Reuters) - Karolinska Development AB :

* Portfolio company Aprea Therapeutics updates clinical data from phase IB trial of APR-246 in ovarian cancer.

* APR-246 can be combined with standard chemotherapy at relevant doses

* Median progression-free survival for 22 evaluable patients, as measured by recist or gcig, was 316 days (95 pct CI, 280-414 days) Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below